Try our mobile app

General information

Country: UNITED STATES

Sector: Medical Devices

Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company"s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
Website: abbott.com


  • Bad financial results growth rate -4.8% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (12.2%)
  • Dividend yield for the last twelve months 2.0%
  • Free cash flow yield -1.1% (LTM)
  • Share price is 16.7% higher than minimum and 25.6% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (20.3x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $6.8 mln (-0.003% of cap.)

Key Financials (Download financials)

Ticker: ABT
Share price, USD:  (-0.6%)105.2699
year average price 106.82  


year start price 110.35 2023-04-20

min close price 90.19 2023-10-12

max close price 120.96 2024-03-08

current price 105.09 2024-04-18
Common stocks: 1 746 881 140

Dividend Yield:  2.0%
FCF Yield LTM: -1.1%
EV / LTM EBITDA: 20.3x
EV / EBITDA annualized: 19.9x
Last revenue growth (y/y):  -2.6%
Last growth of EBITDA (y/y):  -7.0%
Historical revenue growth:  9.1%
Historical growth of EBITDA:  15.2%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 183 894
Net Debt ($m): 8 677
EV (Enterprise Value): 192 571
EBITDA LTM ($m): 9 481
EV / LTM EBITDA: 20.3x
Price to Book: 4.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2024-04-17Investopedia

Abbott Labs Stock Falls as Q2 Guidance Outweighs Earnings Beat

2024-04-17Zacks Investment Research

Q1 Earnings Review

2024-04-17Zacks Investment Research

Markets Try to Shake Off April Blues

2024-04-17Zacks Investment Research

Abbott (ABT) Q1 Earnings Beat Estimates, Margins Contract

2024-04-17Zacks Investment Research

Abbott (ABT) Reports Q1 Earnings: What Key Metrics Have to Say

2024-04-17Zacks Investment Research

Abbott (ABT) Tops Q1 Earnings and Revenue Estimates

2024-04-17Invezz

Abbott beats estimates, reports a 2.2% rise in Q1 sales

2024-04-17Barrons

Abbott Labs Stock Is Slipping. Disappointing Guidance Trumps a Strong Quarter.

2024-04-17Reuters

Abbott beats quarterly profit estimates on strong medical device sales

2024-04-16Zacks Investment Research

Markets Mixed as Q1 Earnings, Powell Control News Headlines
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data